Sign in or create an account to add this stock to your watchlist.
About Zealand Pharma (NASDAQ:ZEAL)
Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics-based medicines in Denmark. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua. The company's product pipeline includes glepaglutide, a long acting GLP-2 analog for the treatment of short bowel syndrome, which has completed Phase 2 clinical trials; and dasiglucagon, a proprietary glucagon analog for various indications comprising as a dual-hormone artificial pancreas for diabetes treatment, rescue treatment for severe hypoglycemia, and congenital hyperinsulinism. The company has collaboration agreements with Sanofi-Aventis Deutschland GmbH and Boehringer Ingelheim GmbH. The company was founded in 1997 and is headquartered in Copenhagen, Denmark.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ZEAL
CUSIPN/A
Phone45-8877-3600
Debt
Debt-to-Equity RatioN/A
Current Ratio11.19
Quick Ratio11.19
Price-To-Earnings
Trailing P/E Ratio-10.84
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$21.23 million
Price / Sales23.23
Cash FlowN/A
Price / CashN/A
Book Value$2.61 per share
Price / Book6.15
Profitability
EPS (Most Recent Fiscal Year)($1.48)
Net Income$-41,350,000.00
Net Margins-461.34%
Return on Equity-75.67%
Return on Assets-52.78%
Miscellaneous
Employees118
Outstanding Shares30,750,000
Zealand Pharma (NASDAQ:ZEAL) Frequently Asked Questions
What is Zealand Pharma's stock symbol?
Zealand Pharma trades on the NASDAQ under the ticker symbol "ZEAL."
How were Zealand Pharma's earnings last quarter?
Zealand Pharma (NASDAQ:ZEAL) posted its quarterly earnings data on Wednesday, March, 7th. The company reported ($0.58) earnings per share (EPS) for the quarter. The company had revenue of $1.78 million for the quarter. Zealand Pharma had a negative return on equity of 75.67% and a negative net margin of 461.34%. View Zealand Pharma's Earnings History.
What price target have analysts set for ZEAL?
4 brokerages have issued 12 month target prices for Zealand Pharma's stock. Their forecasts range from $26.00 to $28.00. On average, they anticipate Zealand Pharma's stock price to reach $27.3333 in the next year. View Analyst Ratings for Zealand Pharma.
What are Wall Street analysts saying about Zealand Pharma stock?
Here are some recent quotes from research analysts about Zealand Pharma stock:
- 1. According to Zacks Investment Research, "Zealand Pharma A/S is a biotechnology company. It focused on the discovery, design and development of peptide-based medicines. Zealand Pharma A/S is based in Copenhagen, Denmark. " (3/15/2018)
- 2. Needham & Company LLC analysts commented, "We recently hosted several meetings with investors and Zealand CEO Britt Jensen. Timelines appear intact for several events over the next 3-4 months, including results from a trial in healthy volunteers evaluating feasibility of once-weekly glepaglutide, presentation of Phase 2 glepaglutide data in Short Bowel Syndrome, initiation of a second Phase 3 dasiglucagon trial for Acute Hypoglycemia, and possibly initiation of a Phase 2/3 trial of dasiglucagon in a single-chamber pump format in Congenital Hyperinsulinism (CHI). Collectively, investors were interested in both glepaglutide and dasiglucagon programs, but individually, were more focused on one or the other. Reiterate BUY. We have not included pump applications of dasiglucagon in our valuation. Progress in the form of a deal with a pump maker and Phase 2/3 trial initiation in CHI would represent an important step forward for the company." (10/16/2017)
Who are some of Zealand Pharma's key competitors?
Some companies that are related to Zealand Pharma include Akcea Therapeutics (AKCA), Xencor (XNCR), Madrigal Pharmaceuticals (MDGL), MyoKardia (MYOK), Motif (MTFB), Phibro Animal Health (PAHC), Prestige Brands (PBH), Aimmune Therapeutics (AIMT), Akorn (AKRX), G1 Therapeutics (GTHX), Cambrex (CBM), ARMO BioSciences (ARMO), PTC Therapeutics (PTCT), Innoviva (INVA) and Zogenix (ZGNX).
Who are Zealand Pharma's key executives?
Zealand Pharma's management team includes the folowing people:
- Ms. Britt Meelby Jensen, Chief Exec. Officer and Pres (Age 45)
- Mr. Mats Peter Blom MBA, Exec. VP & CFO (Age 53)
- Ms. Hanne Heidenheim Bak, Sr. Project Director, R&D Operations Mang. and Director (Age 65)
- Mr. Ivan Møller, Sr. VP of Technical Devel. & Operations
- Dr. Andrew Parker, Exec. VP & Chief Science Officer (Age 53)
When did Zealand Pharma IPO?
(ZEAL) raised $75 million in an initial public offering on Wednesday, August 9th 2017. The company issued 3,900,000 shares at $19.30 per share. Morgan Stanley and Goldman Sachs served as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers.
Has Zealand Pharma been receiving favorable news coverage?
Media coverage about ZEAL stock has trended somewhat positive this week, Accern Sentiment reports. Accern identifies positive and negative media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Zealand Pharma earned a media sentiment score of 0.14 on Accern's scale. They also assigned news articles about the company an impact score of 47.81 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near term.
Who are Zealand Pharma's major shareholders?
Zealand Pharma's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Farallon Capital Management LLC (2.81%), Millennium Management LLC (0.56%) and Jane Street Group LLC (0.04%). View Institutional Ownership Trends for Zealand Pharma.
Which major investors are selling Zealand Pharma stock?
Which major investors are buying Zealand Pharma stock?
How do I buy shares of Zealand Pharma?
Shares of ZEAL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Zealand Pharma's stock price today?
One share of ZEAL stock can currently be purchased for approximately $16.04.
How big of a company is Zealand Pharma?
Zealand Pharma has a market capitalization of $497.56 million and generates $21.23 million in revenue each year. The company earns $-41,350,000.00 in net income (profit) each year or ($1.48) on an earnings per share basis. Zealand Pharma employs 118 workers across the globe.
How can I contact Zealand Pharma?
Zealand Pharma's mailing address is SMEDELAND 36 GLOSTRUP, COPENHAGEN G7, 2600. The company can be reached via phone at 45-8877-3600 or via email at [email protected]
MarketBeat Community Rating for Zealand Pharma (ZEAL)
MarketBeat's community ratings are surveys of what our community members think about Zealand Pharma and other stocks. Vote "Outperform" if you believe ZEAL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZEAL will underperform the S&P 500 over the long term. You may vote once every thirty days.
Zealand Pharma (NASDAQ:ZEAL) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for Zealand Pharma in the last 12 months. Their average twelve-month price target is $27.3333, suggesting that the stock has a possible upside of 70.41%. The high price target for ZEAL is $28.00 and the low price target for ZEAL is $26.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $27.3333 | $27.3333 | $27.3333 | $27.3333 |
| Price Target Upside: | 70.41% upside | 45.08% upside | 45.08% upside | 45.08% upside |
Zealand Pharma (NASDAQ:ZEAL) Consensus Price Target History
Zealand Pharma (NASDAQ:ZEAL) Analyst Ratings History
Show:
(Data available from 5/22/2016 forward)
Zealand Pharma (NASDAQ:ZEAL) Earnings History and Estimates Chart
Zealand Pharma (NASDAQ ZEAL) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 3/7/2018 | Q4 2017 | | ($0.58) | | $1.78 million | View | N/A |  |
| 11/8/2017 | Q3 2017 | ($0.36) | ($0.23) | | $6.33 million | View | N/A | |
| 8/14/2017 | Q2 2017 | | ($0.54) | | $1.60 million | View | N/A | |
| 5/17/2017 | Q1 2017 | | ($0.15) | | $11.12 million | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
Zealand Pharma (NASDAQ:ZEAL) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Zealand Pharma (NASDAQ ZEAL) Insider Trading and Institutional Ownership History
Institutional Ownership Percentage: 10.93%
Zealand Pharma (NASDAQ ZEAL) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
(Data available from 1/1/2013 forward)
Zealand Pharma (NASDAQ ZEAL) News Headlines
| Source: |
|
Zealand Pharma (NASDAQ:ZEAL) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Zealand Pharma (NASDAQ:ZEAL) Income Statement, Balance Sheet and Cash Flow Statement
Zealand Pharma (NASDAQ ZEAL) Stock Chart for Tuesday, May, 22, 2018
Loading chart…
